Last reviewed · How we verify
betaloc
At a glance
| Generic name | betaloc |
|---|---|
| Sponsor | Shengjing Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation (PHASE4)
- Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (PHASE4)
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- Weak Pulse at Yang and Wiry Pulse at Yin Theory (NA)
- BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- betaloc CI brief — competitive landscape report
- betaloc updates RSS · CI watch RSS
- Shengjing Hospital portfolio CI